Zacks Research Issues Positive Estimate for BPMC Earnings
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Research analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Blueprint Medicines in a report issued on Wednesday, May 21st. Zacks Research analyst A. Chakraborty now anticipates that the biotechnology company will post earnings per share of ($0.59) for the quarter, up […]
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Research analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Blueprint Medicines in a report issued on Wednesday, May 21st. Zacks Research analyst A. Chakraborty now anticipates that the biotechnology company will post earnings per share of ($0.59) for the quarter, up […]
